|
Brain
Tumors
|
|
|
Laske
DW, Youle RJ, Oldfield EH
Tumor regression
with regional distribution of the targeted toxin TF-CRM107 in patients with
malignant brain tumors
Nat
Med, 1997 Dec;3(12):1362-8 (Clinical Study, Abstract)
|
|
J.H.
Sampson ; G. Akabani ; G.E. Archer ; D.D. Bigner ; M.S. Berger ; A.H.
Friedman ; H.S. Friedman ; J.E. Herndon II ; S. Kunwar ; S. Marcus ; R.E.
McLendon ; A. Paolino ; K. Penne ; J. Provenzale ; J. Quinn ; D.A. Reardon
; J. Rich ; T. Stenzel ; S. Tourt-Uhlig ; C. Wikstrand ; T. Wong ; R.
Williams ; F. Yuan ; M.R. Zalutsky ; I. Pastan
Progress
Report of a Phase I Study of the Intracerebral Microinfusion of a Recombinant
Chimeric Protein Composed of Transforming Growth Factor (TGF)-α
and a Mutated form of the Pseudomonas Exotoxin Termed PE-38 (TP-38) for
the Treatment of Malignant Brain Tumors
J
Neurooncol,
October 2003, Volume 65, Number, 1, Pages 27 – 35 (Clinical
Study, Abstract)
|
|
J.
H. Sampson, G. Akabani, G. Archer, M. Berger, A. Friedman, H. S.
Friedman, S. Marcus, D. Reardon, D. D. Bigner, I. Pastan
Clinical
outcome and distribution measure of a recombinant chimeric protein
composed of transforming growth factor alpha and a mutated Pseudomonas
exotoxin (TP-38) via convection-enhanced microinfusion on a phase I study
for malignant brain tumor
39th
ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003. Abstract No.
397
(Clinical Study)
|
|
|
|
Glioblastoma
|
|
|
Jing Han, Raj K. Puri
Gene expression profiles of human glioblastoma
cells after treatment with IL-13 cytotoxin invitro by cDNA microarray
analysis
Proceedings
of the AACR, Volume 44, 2nd ed., July 2003, Abstract No. R1040 (Clinical
Study)
|
|
Kunwar S, Pai LH, Pastan I
Cytotoxicity and antitumor effects of growth
factor-toxin fusion proteins on human glioblastoma multiforme cells
J Neurosurg. 1993 Oct;79(4):569-76 (Animal Study, Abstract)
|
|
John H. Sampson, David A. Reardon,
Allan H. Friedman, Henry S. Friedman, R. Edward Coleman, Roger E.
McLendon, Ira Pastan, and Darell D. Bigner
Sustained radiographic and clinical response in patient with bifrontal
recurrent glioblastoma multiforme with intracerebral infusion of the
recombinant targeted toxin TP-38: Case study
Neuro-Oncology, Volume
7, Number 1, Pages 90 -- 96, January 2005. (Case Study, Abstract+)
|
|
|
Madhankumar, A.B., Mintz, Akiva, Debinski,
Waldemar
Interleukin
13
Mutants of Enhanced Avidity Toward the Glioma-Associated Receptor, IL13Rα2
Neoplasia, Volume 6, Number 1, January/February 2004, pp. 15-22(8)
Abstract
| 
Reprint
| 
News
|
|
|
|
Gliomas
|
|
|
A. E.
Frankel, T. F. Liu, A. M. Thorburn, S. B. Tatter, M. C. Willingham
Recombinant toxin DAB389EGF
produces regressions of human glioma xenografts in nude mice
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.3101 (Animal
Study)
|
|
Hagihara N, Walbridge S,
Olson AW, Oldfield EH, Youle RJ
Vascular protection by chloroquine during
brain tumor therapy with Tf-CRM107
Cancer Res, 2000 Jan 15;60(2):230-4. (Laboratory Investigation,
Abstract & PDF Full Text)
|
|
S.
Kunwar, M. Prados, F. Lang, C. Fleming, K. Aldape, P. Gutin, J. Raizer,
J. Piepmeier, M. Berger, R. Puri
Pre- and post-operative infusion of IL13-PE38QQR
cytotoxin by convection-enhanced delivery (CED) in recurrent malignant
glioma: A phase I study
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No.
476
(Clinical Study)
|
|
Laske DW, Ilercil O, Akbasak A, Youle RJ, Oldfield
EH
Efficacy of direct intratumoral therapy with
targeted protein toxins for solid human gliomas in nude mice
J Neurosurg, 1994 Mar;80(3):520-6. (Laboratory Investigation, Abstract)
|
|
M. Prados, S. Kunwar, F. F. Lang, Z.
Ram, M. Westphal, G. Barnett, J. H. Sampson, D. Croteau, R. K. Puri,
for all participating investigators
Final results of Phase I/II studies of
IL13-PE38QQR administered intratumorally (IT) and/or peritumorally
(PT) via convection-enhanced delivery (CED) in patients undergoing
tumor resection for recurrent malignant glioma
2005
ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1506. (Clinical
Study)
Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005:
1506
|
|
Michael
D Prados, Frederick F Lang, Lewis C Stauss, Christina K Fleming,
Kenneth Aldape, Sandeep Kunwar, W K Alfred Yung, Susan M Chang, Syed R
Husain, Philip H Gutin, Jeffrey J Raizer, Joseph M Piepmeier, Mitchel
Berger, Michael McDermott, Raj K Puri
Intratumoral
and intracerebral microinfusion of IL13-PE38QQR cytotoxin: phase I/II
study of pre-and post-resection infusions in recurrent resectable
malignant glioma
38th
ASCO Annual Meeting. Orlando, FL. May 18-21, 2002.
Abstract No.
2087
(Clinical Study)
|
|
N.G.
Rainov, V. Heidecke
Long Term Survival in a Patient with Recurrent
Malignant Glioma Treated with Intratumoral Infusion of an IL4-Targeted
Toxin (NBI-3001)
Journal of Neuro-Oncology, 66 (1-2): 197-201, January 2004 (Case
Report, Abstract+)
|
|
Z.
Ram, G. Barnett, M. Vogelbaum, S. Constantini, K. Lillehei, J.
Sherman, C. Fleming, M. Westphal, M. Mehdorn, R. Puri
Pre-operative infusion of IL13-PE38QQR cytotoxin by
convection-enhanced delivery (CED) in recurrent malignant glioma: A phase
I/II study
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No.
403
(Clinical Study)
|
|
Rand RW, Kreitman RJ, Patronas N,
Varricchio F, Pastan I, Puri RK
Intratumoral
administration of recombinant circularly permuted interleukin-4-Pseudomonas
exotoxin in patients with high-grade glioma
Clin Cancer Res 2000 Jun;6(6):2157-65 (Clinical
Study, Abstract & PDF Full Text)
|
|
Mark
M. Souweidane, Giuseppe Occhiogrosso, Erika B. Mark, Mark A. Edgar
Interstitial Infusion of IL13-PE38QQR in the
Rat Brain Stem
J
Neurooncol, 67 (3): 287-293, May 2004. (Animal Study, Abstract+)
|
|
M.
Weaver, D.W. Laske
Transferrin Receptor Ligand-Targeted Toxin
Conjugate (Tf-CRM107) for Therapy of Malignant Gliomas
J
Neurooncol,
October
2003, Volume 65, Number 1, Pages 3 -- 14 (Clinical
Study, Abstract+)
|
|
J.
Weingart, J. Markert, S. Tatter, M. Rosenblum, J. Fisher, C. Fleming,
J. Steinberg, R. Puri
Determination
of toxicities and maximum tolerated dose (MTD) of intra-tumoral infusion
of IL13-PE38QQR cytotoxin in patients with recurrent supratentorial
malignant glioma: A phase I/II study
39th
ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003. Abstract No.
405
(Clinical Study)
|
|
Jon
Weingart, Lewis Strauss, Stuart A Grossman, James Markert, Stephen
Tatter, Joy D Fisher, Christina Fleming, Raj Puri
Intratumoral
infusion of IL13-PE38QQR cytotoxin for recurrent supratentorial malignant
glioma: phase I/II study
38th
ASCO Annual Meeting. Orlando, FL. May 18-21, 2002.
Abstract No.
2088
(Clinical Study)
|
|
